Executive Clinical Snapshot
Prof. Qing Lv, MD, PhD, is the Director and Chief Physician of the Department of Breast Surgery at West China Hospital, Sichuan University. A nationally and internationally distinguished breast surgical oncologist, Prof. Lv has redefined contemporary breast cancer management by bridging the gap between radical oncologic tumor eradication and reconstructive aesthetics. She is a pioneer of Oncoplastic Breast-Conserving Surgery (OPBCS), immediate prosthetic and autologous reconstructive strategies (including pre-pectoral implant placement and DIEP flaps), and precision systemic therapies for high-risk, aggressive molecular phenotypes such as Triple-Negative Breast Cancer (TNBC) and HER2-positive breast carcinomas.
Academic Leadership & National Standing
- Director & Chief Surgeon, Department of Breast Surgery, West China Hospital, Sichuan University.
- Vice Chairman, Chinese Society of Breast Surgery (CSBrS), Chinese Medical Association.
- Standing Committee Member, Breast Cancer Committee of the Chinese Anti-Cancer Association (CACA-CBCS).
- Chairperson, Sichuan Provincial Breast Cancer Quality Control Committee.
- Principal Investigator & National Lead for multi-center clinical trials evaluating neoadjuvant chemo-immunotherapy in early-stage TNBC and novel antibody-drug conjugates (ADCs) in refractory metastatic breast cancer.
- Core Editorial Board Member for national guidelines on oncoplastic breast surgery and hereditary breast and ovarian cancer syndrome (HBOC).
Surgical & Oncologic Innovations: The Dual-Pursuit Paradigm
Historically, aggressive breast malignancies mandated radical mastectomies, leaving patients with substantial psychological trauma and physical disfigurement. Prof. Lv's philosophy champions "maximum oncologic cure with minimum aesthetic morbidity," optimizing both long-term disease-free survival and patient body image.
Key Clinical Breakthroughs Led by Prof. Qing Lv:
- Advanced Oncoplastic Breast-Conserving Surgery (Level I & II): Utilizes glandular flap transposition, therapeutic mammoplasty, and round-block techniques to excise large or poorly positioned tumors (even those exceeding 4 cm after neoadjuvant shrinkage) while preserving natural breast contour and symmetry.
- Pre-Pectoral Implant-Based Reconstruction: Masters muscle-sparing, pre-pectoral direct-to-implant reconstruction using acellular dermal matrix (ADM) and synthetic mesh, completely avoiding pectoralis major muscle elevation, reducing animation deformity and severe post-operative pain.
- Precision Triple-Negative Breast Cancer Subtyping: Integrates multi-omic classification into daily clinical practice, tailoring platinum-containing neoadjuvant chemotherapy, PARP inhibitors for BRCA-mutated cohorts, and immune checkpoint inhibitors (PD-1/PD-L1) to maximize pathological complete response (pCR) rates beyond 65%.
- Precision Axillary Staging & Lymphedema Prevention: Standardizes reverse axillary mapping (ARM) and indocyanine green (ICG) fluorescence-guided sentinel lymph node biopsy, successfully de-escalating full axillary node dissections to prevent chronic arm lymphedema.
Comprehensive Surgical Spectrum & Clinical Scope
- Oncoplastic Breast-Conserving Surgery (OPBCS): Central, inferior, and medial quadrant resections with contralateral symmetry reduction mammoplasty.
- Immediate & Delayed Breast Reconstruction: Nipple-sparing mastectomy (NSM) with pre-pectoral silicone implants, latissimus dorsi myocutaneous flaps, and microvascular deep inferior epigastric perforator (DIEP) free flaps.
- Triple-Negative Breast Cancer (TNBC): Integrated neoadjuvant chemo-immunotherapy, post-neoadjuvant capecitabine or olaparib maintenance, and clinical trial access for metastatic recurrence.
- HER2-Positive Breast Malignancies: Dual HER2-targeted blockade (trastuzumab + pertuzumab) and innovative antibody-drug conjugate therapies (T-DXd, T-DM1).
- Hereditary & High-Risk Syndromes: Risk-reducing bilateral mastectomy and salpingo-oophorectomy counseling for pathogenic BRCA1/2, PALB2, and TP53 mutation carriers.
Benchmark Clinical Scenarios
Scenario A: Central Invasive TNBC Converted to Complete Pathological Response & Oncoplastic Conservation
A 38-year-old executive was diagnosed with a 4.5 cm Stage IIB basal-like Triple-Negative Breast Cancer directly behind the left nipple-areolar complex with positive axillary lymph nodes. Facing imminent radical mastectomy, she was enrolled into Prof. Lv’s structured neoadjuvant chemo-immunotherapy protocol (nab-paclitaxel, carboplatin, and pembrolizumab). The tumor completely vanished clinically and radiologically. Prof. Lv performed a central oncoplastic lumpectomy with Grisotti flap glandular rotation and targeted axillary dissection. Surgical pathology confirmed pathological complete response (pCR, ypT0 ypN0) with negative surgical margins and outstanding aesthetic preservation.
Scenario B: Bilateral Nipple-Sparing Mastectomy with Immediate Pre-Pectoral Reconstruction for BRCA1 Carrier
A 32-year-old patient with confirmed BRCA1 pathogenic mutation presented with multifocal high-grade ductal carcinoma in situ (DCIS) in the right breast and opted for contralateral risk-reduction. Prof. Lv performed bilateral nipple-sparing mastectomies through inconspicuous inframammary fold incisions, followed by immediate dual-plane pre-pectoral anatomical implant reconstructions with acellular dermal matrix wrapping. The patient avoided chest muscle damage and achieved symmetric, natural cosmetic results.
Scientific Impact & Clinical Research
Prof. Qing Lv has published over 150 papers in prominent oncology journals including JAMA Oncology, Annals of Surgical Oncology, Breast Cancer Research, and The Oncologist. She acts as lead investigator in national multi-center breast cancer clinical trials and frequently delivers keynote addresses at St. Gallen International Breast Cancer Conference and San Antonio Breast Cancer Symposium (SABCS) forums.
International Patient Access via CMCS
International patients seeking expert surgical second opinions, advanced oncoplastic breast conservation, or individualized systemic management for aggressive breast cancer can coordinate with Prof. Qing Lv's multidisciplinary team at West China Hospital via China Medical Concierge – Shanghai (CMCS):
- Multidisciplinary Imaging & Pathology Re-evaluation: Sub-millimeter digital mammography, high-resolution breast MRI, and central pathology/IHC (ER, PR, HER2, Ki-67, PD-L1) slide review prior to travel.
- Virtual Pre-Travel Tumor Board Consultation: Dedicated video evaluation with surgical, medical, and radiation oncology specialists to confirm surgical candidacy and neoadjuvant sequencing.
- Expedited Surgical Scheduling at West China Hospital: Priority admission and operating theater access, minimizing emotional distress and treatment delays.
- Bilingual Clinical Case Management: Comprehensive translation, continuous bedside liaison during surgical hospitalization, wound recovery oversight, and genetic counseling support.
- Cross-Border Systemic Therapy Transition: Structured treatment documentation and cross-border pharmacology coordination with home oncologists for post-surgical endocrine or maintenance therapy.
Connect with CMCS Medical Concierge
For confidential clinical inquiries, breast pathology reviews, or to schedule a consultation with Prof. Qing Lv:
Email: contract@medicalsh.com
WhatsApp: Connect on WhatsApp
Official Website: www.medicalsh.com
댓글 0개